Avatrombopag
Avatrombopag[edit | edit source]
Avatrombopag is a medication used primarily to treat thrombocytopenia, a condition characterized by abnormally low levels of platelets in the blood. It is particularly used in patients with chronic liver disease who are scheduled to undergo a medical or dental procedure, as well as in patients with chronic immune thrombocytopenic purpura (ITP).
Mechanism of Action[edit | edit source]
Avatrombopag is a thrombopoietin receptor agonist. It works by stimulating the production of platelets in the bone marrow. The drug binds to the thrombopoietin receptor on the surface of megakaryocytes and their precursors, promoting their proliferation and differentiation into platelets. This mechanism helps increase platelet counts in patients with thrombocytopenia.
Clinical Use[edit | edit source]
Avatrombopag is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. It is also used in adult patients with chronic immune thrombocytopenic purpura who have had an insufficient response to previous treatment.
Administration[edit | edit source]
Avatrombopag is administered orally. The dosage and duration of treatment depend on the specific condition being treated and the patient's platelet count. It is important for patients to follow their healthcare provider's instructions regarding dosage and administration.
Side Effects[edit | edit source]
Common side effects of avatrombopag include headache, fatigue, and nausea. Serious side effects may include thromboembolic events, such as deep vein thrombosis or pulmonary embolism. Patients should be monitored for signs of increased platelet counts and potential thrombotic complications.
Pharmacokinetics[edit | edit source]
Avatrombopag is absorbed in the gastrointestinal tract and reaches peak plasma concentrations approximately 3 to 6 hours after administration. It is metabolized primarily in the liver and excreted in the feces. The half-life of avatrombopag is approximately 19 hours, allowing for once-daily dosing.
Development and Approval[edit | edit source]
Avatrombopag was developed by Eisai Co., Ltd., a Japanese pharmaceutical company. It was approved by the U.S. Food and Drug Administration (FDA) in 2018 for the treatment of thrombocytopenia in patients with chronic liver disease scheduled to undergo a procedure. It was later approved for use in patients with chronic immune thrombocytopenic purpura.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD, Sushmitha Nalluri
